Portal's platform puts hard-to-deliver cargo into the cytosol

Portal's technology enables delivery of proteins, RNPs, mRNA, and impermeable small molecules straight into the cytosol, with the cell intact. Used by 100+ partners, including 10 of the top pharma.

How does it work?

Portal's technology creates a physical way to get molecules into cells by pushing them through a constriction slightly smaller than they are. This opens the membrane momentarily, allowing material in the buffer to diffuse directly into the cytosol, before the cell reseals. No virus, no electrical pulse, no lipid carrier, and nothing about the cargo has to be re-engineered to get in.

PEER-REVIEWED FOUNDATION

The underlying methodology behind Portal's technology traces back to a peer-reviewed PNAS paper from MIT.

Sharei, Zoldan, Adamo, et al. "A vector-free microfluidic platform for intracellular delivery." Proceedings of the National Academy of Sciences, 2013.

What Portal's Platform does Differently

No vector, no pulse, no carrier

A physical squeeze does the work, so delivery does not depend on the chemistry of the cargo.

Gentle on the cell

Cells keep their phenotype and function, with no electrical or lipid damage.

Works across cells and cargo

Proteins, RNPs, mRNA, peptides, degraders, and impermeable compounds, across primary cells and lines.

Bench to GMP

The same method from a benchtop run to more than a billion cells a minute.

No vector, no pulse, no carrier

A physical squeeze does the work, so delivery does not depend on the chemistry of the cargo.

Gentle on the cell

Cells keep their phenotype and function, with no electrical or lipid damage.

Works across cells and cargo

Proteins, RNPs, mRNA, peptides, degraders, and impermeable compounds, across primary cells and lines.

Bench to GMP

The same method from a benchtop run to more than a billion cells a minute.

Key Capabilities of Portal's Platform

89% of T cells co-received a CRISPR RNP, mRNA, and dextran (Control vs Boost).

Multiplex delivery: three cargos into the same T cells in one boost

A single boost co-delivers a CRISPR RNP, an mRNA, and a dextran into the same resting T cells, and most cells receive all three at once. Doing it in one operation, rather than sequential rounds of electroporation or transfection, avoids the compounding stress and cell loss of handling the same cells three times.

For a CAR-T or multiplexed-edit workflow, the edit, the transgene, and a trackable label can land together in a single gentle step.

CD34+ cells: electroporation misregulates genes broadly; levels for boosted cells stay near baseline.

Boosting keeps gene expression near baseline

Boosted cells barely shift their transcriptome, while electroporation misregulates gene expression broadly within hours of treatment. Because the cells you assay behave normally, the readout reflects the perturbation you introduced rather than the stress of the delivery itself.

Across a full high-throughput run, viability stays high dispense after dispense, so the population you screen is the one you started with.

GFP mRNA delivered into iPSCs (fluorescence vs transmitted light).

iPSCs keep their pluripotency after a boost

iPSCs take up delivered mRNA while staying viable and holding their pluripotency markers, and they still differentiate normally afterward, here into dopaminergic neurons. Stem and progenitor cells are the ones most easily pushed off their fate by harsh delivery, so preserving identity matters as much as delivery efficiency.

A boost engineers these cells without trading away their differentiation potential.

GFP mRNA reaches T (CD3+), B (CD19+), NK (CD56+), and monocyte (CD14+) subsets in unseparated PBMCs.

Every PBMC subset in one boost, without pre-isolation

One boost delivers GFP mRNA into every subset of an unseparated PBMC sample, T cells, B cells, NK cells, and monocytes alike. You can engineer straight from a patient sample or a thawed PBMC vial without a sorting or isolation step that costs cells, time, and yield.

That makes it practical to work with the mixed populations that primary-cell biology actually comes in.

Delivery increases with macrocycle concentration (flow histograms).

Impermeable compounds reach the cytosol and show dose-dependent activity

Membrane-impermeable peptides and small molecules that typically can't cross on their own, are able to reach the cytosol when boosted. Delivery scales cleanly with the dose you load. Cells stay viable across the concentration range, so you can build a real dose-response instead of a single endpoint.

Chemical matter that reads as inactive only because it can't get in can finally be tested against its target inside the cell.

How it compares to other delivery methods

Method	Best at	Limitations
Electroporation / nucleofection	Nucleic acids, RNPs	Stresses the cell; often needs pre-activation
Lipofection / LNP	Nucleic acids	No proteins or small molecules; weak in primary cells
Viral (AAV, lentiviral)	Long-term expression	Slow, costly, cargo-size limits, insertional risk
Portal's method	Proteins, RNPs, mRNA, impermeable compounds	Plasmid DNA reaches the cytosol, not the nucleus

Portal's Platform for Drug Discovery

Boost otherwise cell-impermeable degraders, kinase tracers, and library probes straight into the cytosol, so assays that depend on getting a compound inside the cell can be read without relying on passive uptake. The panels below show dose-response degradation, intracellular target engagement, live-cell degradation kinetics, and DNA-encoded library screening, each measured after a boost.

PROTAC LC-2 titrated from 0 to 10 uM in cells with a luminescent degradation reporter; luminescence, normalized to the 0 uM control, falls with dose as the target is degraded, while untreated, no-boost, and no-cargo controls give no signal.

PROTAC dose-response read by intracellular luminescence

Boosting gets a cell-impermeable PROTAC straight into the cytosol, so a dose-response can be built from the intracellular concentration rather than from passive uptake. The PROTAC LC-2 was titrated in cells carrying a luminescent degradation reporter, and target signal falls step-wise as the dose increases.

Because the delivered amount scales with how much cargo is loaded, each point on the curve reflects a controlled intracellular dose.

Ponatinib titration in NanoLuc-Src HeLa cells: the boosted tracer gives a high BRET ratio at 0 uM that falls with inhibitor dose, while no-boost controls stay flat.

Intracellular target engagement measured by NanoBRET

NanoLuc-Src HeLa cells were dosed with the Src inhibitors ponatinib or bosutinib, and an impermeable NanoBRET kinase tracer was boosted into the cytosol. The BRET ratio decreases as inhibitor concentration rises across a 0 to 10 uM range, reporting displacement of the tracer and loss of intracellular kinase engagement.

Boosting the tracer in produces the on-target signal that no-boost controls do not, so engagement can be quantified in live cells.

POI degrader kinetics over ~22 hours: the boosted sample (red) degrades faster and reaches a lower plateau (~30% of DMSO) than the non-boosted sample (blue, ~70%).

Live-cell degradation kinetics with a luminescent reporter

Cells carrying a luminescent degradation reporter were read continuously after degrader treatment, with the compound either boosted in or left to enter passively. The boosted trace drops to about 30% of the DMSO signal within roughly 12 hours, while the non-boosted trace plateaus near 70%. In other words, Portal's platform allows for faster and deeper degradation.
A live-cell titration of VH298 in the same reporter format returns a clean concentration-response, confirming the readout tracks intracellular ligand dose.

Percent probe-positive live HeLa cells: ~89% after boost versus ~0% in the control.

DNA-encoded library screening inside live cells

A DNA-encoded library probe, which does not cross the membrane on its own, was boosted into HeLa cells and measured by flow cytometry. About 89% of live cells become probe-positive after the boost versus essentially none in the no-boost control, and the histogram shows the whole population shifting to higher DEL-probe signal.
This puts the library inside intact cells, so binding can be screened against intracellular targets rather than isolated protein.

Proven in partner labs

Groups at pharma and academic labs put Portal's platform to work on their own cells and cargo. Each talk below walks through what the team ran and what they found.

WEBINAR

Merck: Degrader permeability without a stable cell line

Merck's discovery group reads degrader permeability and target engagement by boosting the reporter straight into their own cells, rather than building and maintaining a stable line for every target. Delivering a VHL-NanoLuc reporter into AsPC-1 cells lets the team measure degrader activity and kinetics in the relevant cell background, and a p53/MDM2 peptide assay in HCT116 on an automation-integrated Galaxy returns high viability and delivery.

View talk

WEBINAR

ABBVIE Rescuing compounds that read as inactive

AbbVie's Small Molecule Therapeutics and Platform Technologies group shows how permeability can hide real compounds, turning active ones into false negatives in a standard assay. Boosting impermeable compounds directly into the cytosol recovers activity that passive uptake misses, including a BRD4 degrader that moves from 82% to 50% protein remaining, while permeable controls behave the same with or without a boost.

View talk

One method, three scales

Gateway

Research Scale

Benchtop instrument for discovery research

0.5-10M cells per run

50-200 µl volume range

Compact benchtop unit that fits in any hood

Available now

Galaxy-i

High-Throughput Screening

High throughput scale instrument for screening applications with multi well plates.

96/384-well plate compatibility

Integrate with existing automation

Ideal for DEL, PROTAC, CRISPR screening

Available now

Millibooster

Clinical Manufacturing

GMP-ready clinical production system

1 billion+ cells/minute throughput

Attach to existing equipment via tube-weld or luer lock connection

2-100mL volume range

Available Now

Broad Compatibility

Portal’s platform supports delivery to a diverse range of cell types and cargoes

Delivery materials

Validated cell types

mRNA, siRNA, saRNA

Proteins & Peptides

CRISPR RNPs

Small Molecules

Polymers

Nanoparticles

Antibodies

Virus

PBMCs

T cells

B cells

NK cells

iPSCs

Monocytes

RBCs

HSCs

Delivery materials

mRNA, siRNA, saRNA

Proteins & Peptides

CRISPR RNPs

Small Molecules

Polymers

Nanoparticles

Antibodies

Virus

Validated cell types

PBMCs

T cells

B cells

NK cells

iPSCs

Monocytes

RBCs

HSCs

Try it on your own cells

Tell us your cargo and cell type, and one of our scientists will share how Portal could make an impact on your workflow.

How does Portal's technology work?Cells flow through a constriction slightly smaller than they are, which opens the membrane for a moment. Whatever is in the surrounding buffer diffuses straight into the cytosol, and the cell seals back up. There is no virus, no electrical pulse, and no lipid carrier, so nothing about the cargo has to be re-engineered to get in.

How is Portal's delivery method different from electroporation?There is no high-voltage pulse, so the cells stay closer to their untreated state. In CD34+ cells, Portal's delivery method keeps the transcriptome near baseline while electroporation misregulates genes broadly within hours. It also works in resting cells, so there is no pre-activation step.

What can it deliver?Proteins, antibodies, CRISPR RNPs, mRNA (including unmodified), circRNA, siRNA, peptides, macrocycles, degraders, DELs, and impermeable small molecules. Plasmid DNA is the exception: it reaches the cytosol but not the nucleus.

Can I deliver more than one cargo at once?Yes. A single boost co-delivers several cargos into the same cells. In resting T cells, one boost put a CRISPR RNP, an mRNA, and a dextran into about 89% of cells at once, so an edit, a transgene, and a label can land together instead of in sequential rounds of transfection.

Is the cargo still functional once it is inside?Yes. Delivered degraders drive target degradation, boosted kinase tracers report intracellular target engagement, and delivered mRNA expresses, so the readout reflects what the cargo does rather than just whether it got in.

Do my cells need to be pre-activated?No. Delivery works in resting primary cells, including unstimulated T cells, without a stimulation step.

Which cell types has it been validated in?Primary and stem cells that are usually hard to deliver into, including resting and stimulated T cells, NK cells, B cells, monocytes, dendritic cells, TILs, whole PBMCs, CD34+ HSCs, iPSCs, neurons, and whole blood, alongside common cell lines. Everything runs in suspension.

Portal's platform puts hard-to-deliver cargo into the cytosol

How does it work?

The underlying methodology behind Portal's technology traces back to a peer-reviewed PNAS paper from MIT.

What Portal's Platform does Differently

Multiplex delivery: three cargos into the same T cells in one boost

Boosting keeps gene expression near baseline

iPSCs keep their pluripotency after a boost

Every PBMC subset in one boost, without pre-isolation

Impermeable compounds reach the cytosol and show dose-dependent activity

How it compares to other delivery methods

PROTAC dose-response read by intracellular luminescence

Intracellular target engagement measured by NanoBRET

Live-cell degradation kinetics with a luminescent reporter

DNA-encoded library screening inside live cells

Proven in partner labs

Merck: Degrader permeability without a stable cell line

ABBVIE Rescuing compounds that read as inactive

One method, three scales

Gateway

Benchtop instrument for discovery research

Galaxy-i

High throughput scale instrument for screening applications with multi well plates.

Millibooster

GMP-ready clinical production system

Broad Compatibility

Portal’s platform supports delivery to a diverse range of cell types and cargoes

Try it on your own cells

Questions before your first run